As part of AP&T’s peer-review process, a technical check of this meta-analysis was performed by Dr P. Collins.
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis
Article first published online: 22 AUG 2011
© 2011 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 34, Issue 8, pages 901–910, October 2011
How to Cite
Triantos, C. K., Koukias, N. M., Nikolopoulou, V. N. and Burroughs, A. K. (2011), Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics, 34: 901–910. doi: 10.1111/j.1365-2036.2011.04822.x
- Issue published online: 20 SEP 2011
- Article first published online: 22 AUG 2011
- Publication data Submitted 16 May 2011 First decision 31 May 2011 Resubmitted 4 July 2011 Accepted 1 August 2011
Aliment Pharmacol Ther 2011; 34: 901–910
Background There is no satisfactory medical treatment for patients with primary sclerosing cholangitis. There are conflicting data regarding the clinical benefit of high doses of ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis.
Aim To evaluate using meta-analysis, if UDCA (standard or high-dose) is useful in primary sclerosing cholangitis.
Methods We searched MEDLINE using the textwords ‘PSC’, ‘treatment’, ‘UDCA’ and retrieved all abstracts from the major Gastroenterology and Liver meetings. We included randomised clinical trials comparing standard or high-dose of UDCA (>15 mg/kg body weight per day) vs. placebo or no intervention. End-points: mortality or liver transplantation, pruritus, fatigue, cholangiocarcinoma and histological progression.
Results We identified eight randomised clinical trials comprising 567 patients. Five used standard doses and three high doses of UDCA. There was no significant difference in mortality [OR, 0.6 (95% CI, 0.4–1.4)], in pruritus [OR, 1.5 (95% CI, 0.3–7.2)], in fatigue [OR, 0.0 (95% CI, 0.1–7.7)], in cholangiocarcinoma [OR, 1.7 (95% CI, 0.6–5.1)] and in histology stage progression [OR, 0.9 (95% CI, 0.34–2.44)]. No differences were found in the subgroup analyses.
Conclusion Neither standard nor high-dose UDCA influence favourably the progression of primary sclerosing cholangitis.